Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Fosun Pharma Pays $36 Million to Acquire GSK Suzhou Manufacturing Facility

publication date: Jul 9, 2019

Shanghai Fosun Pharma paid $36 million to buy an older GlaxoSmithKline drug making facility in Suzhou, along with non-exclusive rights to manufacture lamivudine, a GSK treatment for hepatitis B/HIV. Last week, GSK officially opened a new $95 million Singapore facility that uses an enzyme-based continuous manufacturing process. The process is less expensive and more friendly to the environment than traditional chemical synthesis. Initially, GSK's new facility will produce Daprodustat, an oral treatment for anemia associated with chronic kidney disease. More details....

Stock Symbols: (SHA: 600196; HK: 2196) (NYSE: GSK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.